A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

Phase 2 Completed 78 enrolled Amgen

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of VIB4920 (formerly MEDI4920) in adult participants with rheumatoid arthritis (RA).

Timeline

Start: 2019-12-09
Primary completion: 2021-12-28
Completion: 2021-12-28

Publications

Kivitz A, Wang L, Alevizos I, Gunsior M, Falloon J, Illei G, St Clair EW. The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis. RMD Open. 2023 Aug;9(3):e003317. doi: 10.1136/rmdopen-2023-003317.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dazodalibep	Protein / enzyme biologic	1500 mg	Intravenous
Subject	Dazodalibep	Protein / enzyme biologic	3000 mg	Intravenous

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

Summary

Timeline

Publications

Drugs

Indications